^
Association details:
| Biomarker: | SSTR positive |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | Actinium-225 DOTATATE (RYZ101) (α radiation emission, SSTR2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1198P - Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings
Published date:
10/16/2023
Excerpt:
ACTION-1 (NCT05477576) is a 2-part, global, randomized, controlled, open-label, phase 1b/3 trial of RYZ101 in advanced, well-differentiated SSTR+ GEP-NETs progressing after 177Lu-SSA therapy. Herein, we report results from the phase Ib portion of the trial....Confirmed objective response was seen in 5 evaluable pts....Initial data suggest promising efficacy.
Trial ID:
